University of South Florida
Orally Administered Nanoscale Drug Delivery System for Colorectal Cancer
Abstract
dc:descriptionMithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved chemotherapeutic agent that is used for the treatment of testicular cancer. According to previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC) and cancer stem cells (CSCs) which are responsible for a highly invasive and metastatic forms of CRC. The use of Mit-A as chemotherapy is limited in CRC due to its toxicity. To minimize its toxicity, we have developed an orally delivered nanoscale drug delivery system by which Mit-A can be delivered using biocompatible and biodegradable materials. Mit-A nanoparticles were prepared using Poly(lactic-co-glycolic acid) as the inner core and chitosan (CS) on the outer shell of nanoparticles having an average size of 166.66 ± 0.86 nm and were dispersed in alginate/chitosan double crosslinked hydrogel which release the payload at the colonic site to target CRC and CSCs thus, contributing to total cancer therapy. In-vitro and in-vivo results show that oral administration of Mit-A nanoparticles dispersed in hydrogel have a decreased toxicity and can reduce the tumor burden in an orthotopic CRC mouse model. Taken together, an orally administered nanoscale drug delivery system of Mit-A nanoparticles dispersed in the hydrogel is a promising drug delivery system to target CRC and CSCs with reduced toxicity.
Degree
thesis:*- Name thesis:degree_name
- Master of Science (M.S.)
- Level thesis:degree_level
- Thesis
- Discipline thesis:degree_discipline
- Graduate School
- Grantor
- University of South Florida
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Shah, Bhavya
- Contributors dc:contributor
-
- Subhra Mohapatra, Ph.D.
- Shyam Mohapatra, Ph.D.
- Eleni Markoutsa, Ph.D.
Subjects
dc:subject × 7Identifiers
dc:identifier.*- Repository record dc:identifier
- https://digitalcommons.usf.edu/etd/8994